Ningxia Zhongke Biotechnology Co., Ltd (SHA:600165)
China · Delayed Price · Currency is CNY 3.890
-0.070 (-1.77%)
Feb 27, 2026, 3:00 PM CST
SHA:600165 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 485.6 | 342.78 | 279.46 | 679.35 | 246.77 | 113.87 |
Other Revenue | 2.54 | 2.54 | 6.23 | 1.79 | 1.95 | 5.24 |
| 488.14 | 345.32 | 285.69 | 681.13 | 248.72 | 119.11 | |
Revenue Growth (YoY) | 61.85% | 20.87% | -58.06% | 173.86% | 108.80% | -55.18% |
Cost of Revenue | 703.21 | 478.62 | 419.41 | 634.69 | 387.14 | 107.72 |
Gross Profit | -215.07 | -133.3 | -133.72 | 46.45 | -138.43 | 11.4 |
Selling, General & Admin | 68.82 | 60.83 | 52.75 | 102.07 | 36.57 | 25.63 |
Research & Development | 29.41 | 12.48 | 13.87 | 25.51 | 20.21 | 0.96 |
Other Operating Expenses | 11.4 | 7.76 | 2.9 | 6.16 | 5.29 | -0.97 |
Operating Expenses | 112.82 | 81.29 | 68.35 | 133.85 | 61.79 | 25.59 |
Operating Income | -327.89 | -214.59 | -202.08 | -87.41 | -200.22 | -14.2 |
Interest Expense | -56.75 | -145.36 | -142.52 | -91.88 | -31.28 | -23.15 |
Interest & Investment Income | - | 0.02 | 34.36 | 35.67 | 40.5 | 42.6 |
Currency Exchange Gain (Loss) | 0.9 | 0.9 | 0.58 | 1.92 | -0.62 | -0.32 |
Other Non Operating Income (Expenses) | 15.85 | 0.12 | -0.71 | -0.41 | -0.04 | 12.93 |
EBT Excluding Unusual Items | -367.89 | -358.91 | -310.37 | -142.1 | -191.66 | 17.86 |
Gain (Loss) on Sale of Investments | 163.28 | -83.26 | - | - | - | - |
Gain (Loss) on Sale of Assets | 4.55 | -2.37 | 0.21 | -0.06 | 2.1 | -0.01 |
Asset Writedown | -104.43 | -118.56 | -185.07 | -23.66 | - | -2.12 |
Legal Settlements | - | - | - | - | - | -0.28 |
Other Unusual Items | -57.65 | -15.97 | -20.32 | 0.07 | 2.51 | 4.62 |
Pretax Income | -362.14 | -579.07 | -515.54 | -165.75 | -187.05 | 20.07 |
Income Tax Expense | -2.36 | -2.04 | -0.28 | 4.36 | 2.39 | -3.13 |
Earnings From Continuing Operations | -359.78 | -577.03 | -515.26 | -170.11 | -189.44 | 23.2 |
Minority Interest in Earnings | 49.44 | 38.12 | 50.55 | 28.62 | 23.35 | -2.29 |
Net Income | -310.34 | -538.91 | -464.71 | -141.48 | -166.09 | 20.91 |
Net Income to Common | -310.34 | -538.91 | -464.71 | -141.48 | -166.09 | 20.91 |
Shares Outstanding (Basic) | 685 | 685 | 684 | 683 | 683 | 674 |
Shares Outstanding (Diluted) | 685 | 685 | 684 | 683 | 683 | 674 |
Shares Change (YoY) | 0.00% | 0.05% | 0.13% | 0.00% | 1.35% | -0.98% |
EPS (Basic) | -0.45 | -0.79 | -0.68 | -0.21 | -0.24 | 0.03 |
EPS (Diluted) | -0.45 | -0.79 | -0.68 | -0.21 | -0.24 | 0.03 |
Free Cash Flow | -364.39 | -91.39 | -34.53 | -6.17 | -258.32 | -773.96 |
Free Cash Flow Per Share | -0.53 | -0.13 | -0.05 | -0.01 | -0.38 | -1.15 |
Gross Margin | -44.06% | -38.60% | -46.81% | 6.82% | -55.66% | 9.57% |
Operating Margin | -67.17% | -62.14% | -70.73% | -12.83% | -80.50% | -11.92% |
Profit Margin | -63.58% | -156.06% | -162.66% | -20.77% | -66.78% | 17.55% |
Free Cash Flow Margin | -74.65% | -26.47% | -12.09% | -0.91% | -103.86% | -649.76% |
EBITDA | -208.7 | -87.56 | -64.59 | 35.08 | -140.73 | 0.38 |
EBITDA Margin | -42.75% | -25.36% | -22.61% | 5.15% | -56.58% | 0.32% |
D&A For EBITDA | 119.19 | 127.03 | 137.48 | 122.48 | 59.49 | 14.58 |
EBIT | -327.89 | -214.59 | -202.08 | -87.41 | -200.22 | -14.2 |
EBIT Margin | -67.17% | -62.14% | -70.73% | -12.83% | -80.50% | -11.92% |
Revenue as Reported | 488.14 | 345.32 | 285.69 | 681.13 | 248.72 | 119.11 |
Advertising Expenses | - | 0.42 | 0.26 | 0.31 | 0.14 | 0.12 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.